Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

被引:46
作者
Citron, D. M. [2 ]
Babakhani, F. [1 ]
Goldstein, E. J. C. [2 ]
Nagaro, K. [3 ]
Sambol, S. [3 ]
Sears, P. [1 ]
Shue, Y. -K. [1 ]
Gerding, D. N. [3 ,4 ]
机构
[1] Optimer Pharmaceut Inc, San Diego, CA 92121 USA
[2] RM Alden Res Lab, Culver City, CA USA
[3] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA
[4] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA
关键词
Clostridium; Difficile; OPT-80; Fidaxomicin; PAR-101; CDI; IN-VITRO ACTIVITIES; CLOSTRIDIUM-DIFFICILE; METRONIDAZOLE; EPIDEMIC; DIARRHEA; DISEASE; AGENTS;
D O I
10.1016/j.anaerobe.2009.09.005
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Background: Clostridium difficile infection (CDI) has been increasing in incidence and severity in recent years, coincident with the spread of a "hypervirulent" strain, REA type BI (ribotype 027, PFGE NAP 1). Exacerbating the problem has been the observation that metronidazole may be showing decreased effectiveness, particularly in the more severe cases. Fidaxomicin is an 18-membered macrocycle currently in phase 3 trials for the treatment of C. difficile infection (CDI). An open-label, phase II study in CDI patients has been completed and the clinical results published. C. difficile organisms were isolated from patient stool specimens and typed by restriction endonuclease analysis (REA) in order to determine the frequency and susceptibility of the C. difficile isolates and their response to treatment. Methods: Fecal samples were plated on CCFA agar for isolation of C. difficile. These isolates were tested for susceptibility to fidaxomicin, vancomycin, and metronidazole using CLSI agar dilution methods and were typed by REA. Results: C. difficile was isolated from 38 of 49 subjects and 16 (42%) were the epidemic C. difficile BI group. The BI strain was distributed approximately equally in the three dosing groups. Overall antibiotic susceptibilities were consistent with the previously reported MIC90 values for the three antibiotics tested, but the MIC90 of BI strains was two dilutions higher than non-BI strains for metronidazole and vancomycin (for both antibiotics, MIC90 was 2 mu g/mL vs. 0.5 mu g/ml, P < 0.01 for metronidazole, P = NS for vancomycin). Clinical cure for BI isolates (11/14, 79%) was not significantly different from non-BI isolates (21/22, 95%). Conclusion: These results underscore the high prevalence of the BI epidemic strain and demonstrate that mild to moderate CDI infection as well as severe disease can be caused by these strains. Fidaxomicin cure rates for subjects with BI and with non-BI strains are similar, although the small numbers of subjects preclude a robust statistical comparison. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:234 / 236
页数:3
相关论文
共 21 条
[1]
[Anonymous], EUR SURVEILLANCE
[2]
Treatment of Clostridium difficile-associated disease:: old therapies and new strategies [J].
Aslam, S ;
Hamill, R ;
Musher, DM .
LANCET INFECTIOUS DISEASES, 2005, 5 (09) :549-557
[3]
FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE [J].
BOLTON, RP ;
CULSHAW, MA .
GUT, 1986, 27 (10) :1169-1172
[4]
BRAZIER JS, 2008, EUROSURVEILLANCE, V41, P1
[5]
Brazier JS., 2008, EUROSURVEILLANCE, V13, P1
[6]
DEVELOPMENT OF A RAPID AND EFFICIENT RESTRICTION-ENDONUCLEASE ANALYSIS TYPING SYSTEM FOR CLOSTRIDIUM-DIFFICILE AND CORRELATION WITH OTHER TYPING SYSTEMS [J].
CLABOTS, CR ;
JOHNSON, S ;
BETTIN, KM ;
MATHIE, PA ;
MULLIGAN, ME ;
SCHABERG, DR ;
PETERSON, LR ;
GERDING, DN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (07) :1870-1875
[7]
*CLSI NCCLS, 2007, M11A7 CLSI NCCLS
[8]
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species [J].
Credito, KL ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) :4430-4434
[9]
Clostridium difficile toxin synthesis is negatively regulated by TcdC [J].
Dupuy, B. ;
Govind, R. ;
Antunes, A. ;
Matamouros, S. .
JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 57 (06) :685-689
[10]
In vitro activities of OPT-80 and comparator drugs against intestinal bacteria [J].
Finegold, SA ;
Molitoris, D ;
Vaisanen, ML ;
Song, YL ;
Liu, CX ;
Bolaños, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4898-4902